Eupraxia Pharmaceuticals Posts Strong Histologic Gains in Mid-Stage EoE Trial for EP-104GI

Eupraxia Pharmaceuticals ( (TSE:EPRX) ) has shared an update.

Eupraxia Pharmaceuticals on May 6, 2026 reported the first EoE Histology Scoring System (EoEHSS) sub-score data from the ongoing Phase 1b/2a portion of its RESOLVE trial of EP-104GI in eosinophilic esophagitis, with results also presented at the Digestive Disease Week conference in Chicago. The analysis showed improvements in inflammation (EoEHSS-i) across all reported cohorts and in tissue architecture and fibrosis (EoEHSS-a) across most cohorts at both 12 and 36 weeks, with the strongest responses at the highest dose.

In patients receiving the top dose (cohort 9), EoEHSS inflammatory grade and stage improved by more than 90% and architectural/fibrotic measures by more than 83% at 12 and 36 weeks, supporting earlier symptom and endoscopic (EREFS) findings that EP-104GI may meaningfully improve esophageal tissue health. These early histologic data bolster Eupraxia’s positioning in the emerging EoE treatment market and de-risk dose selection for the randomized Phase 2b portion of RESOLVE, which is now recruiting 120 mg and 160 mg regimens and is expected to deliver top-line results in the fourth quarter of 2026.

The RESOLVE Phase 1b/2a study is a multicenter, open-label, dose-escalation trial in adults with active EoE, using a single session of 4 to 20 esophageal wall injections with escalating dose per site and number of sites, and follow-up to 24 weeks in early cohorts and up to 52 weeks in higher-dose cohorts. By demonstrating durable histologic improvements out to 36 weeks in several cohorts, the data suggest EP-104GI’s local injection strategy could offer a sustained, tissue-targeted alternative to systemic therapies for EoE, with implications for broader use of Eupraxia’s Diffusphere platform in other localized inflammatory diseases.

The most recent analyst rating on (TSE:EPRX) stock is a Buy with a C$14.00 price target. To see the full list of analyst forecasts on Eupraxia Pharmaceuticals stock, see the TSE:EPRX Stock Forecast page.

Spark’s Take on EPRX Stock

According to Spark, TipRanks’ AI Analyst, EPRX is a Neutral.

The score is held back primarily by the pre-revenue model with widening losses and rising cash burn, despite a notably improved, low-debt balance sheet. Technical indicators also reflect weak near-term momentum, and valuation signals are limited by negative earnings and lack of dividend support.

To see Spark’s full report on EPRX stock, click here.

More about Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company developing locally delivered, extended-release therapies for conditions with high unmet medical need. Its proprietary Diffusphere polymer-based microsphere platform is designed for targeted, long-acting drug delivery, with a focus on pain and inflammatory gastrointestinal diseases, and potential applications in oncology, infectious disease and other areas.

The company’s lead programs include EP-104GI, an injectable esophageal wall treatment for eosinophilic esophagitis (EoE), now in the RESOLVE Phase 1b/2 trial, and EP-104IAR for knee osteoarthritis pain, which achieved its primary and most secondary endpoints in a completed Phase 2b trial. Eupraxia is also building a pipeline of long-acting formulations for additional inflammatory joint and oncology indications, aiming to improve safety, tolerability and duration versus existing therapies.

Average Trading Volume: 75,014

Technical Sentiment Signal: Buy

Current Market Cap: C$625.6M

For an in-depth examination of EPRX stock, go to TipRanks’ Overview page.